Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Sex-related differences in time-to-onset of immune checkpoint inhibitor-related interstitial lung disease: a JADER pharmacovigilance study
Naohito Ide; Minori Yamashita; Miyako Yamashita; Ryusuke Watanabe; Chika Moriya; Rin Yagome; Ken-ichi Sako; Tomoji MaedaShow moreShow less
1. Department of Clinical Pharmacology, Nihon Pharmaceutical UniversityShow moreShow less
Time-dependent indirect comparison of enfortumab vedotin plus pembrolizumab and disitamab vedotin plus toripalimab in advanced urothelial carcinoma
Hiroki Tanaka; Hiroshi Fukushima; Wei Chen; Fei Li; Soichiro Yoshida; Yasuhisa FujiiShow moreShow less
1. Department of Urology, Institute of Science Tokyo; 2. Department of Urology, Zigong Fourth People’s Hospital; 3. Department of Urology, Nanfang Hospital, Southern Medical UniversityShow moreShow less
Integrative topological and longitudinal transcriptomic analyses identify a 14-gene interferon-stimulated module associated with acquired sunitinib resistance in clear cell renal cell carcinoma
Wenhao Chu; Fuhao Wang; Liangkuan Bi; Xing FuShow moreShow less
1. Department of Urology, the First Affiliated Hospital of Anhui Medical University; 2. Department of Urology, Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, and Shenzhen Clinical Research Center for Urology and Nephrology, Peking University Shenzhen Hospital; 3. School of Medicine, Southern University of Science and TechnologyShow moreShow less
Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance – a review
Lingyun Zhou; Jintao He; Wenbing Huang; Zhengliang Li; Min Yu; Jiangyan Li; Wenzhong Yang; Wei XiongShow moreShow less
1. Department of Biochemistry and Molecular Biology, Health Science Center, College of Basic Medical Sciences, Dali University; 2. Key Laboratory of Clinical Biochemistry Testing in Universities of Yunnan Province, Health Science Center, School of Basic Medical Sciences, Dali University; 3. Department of Radiology, The First Affiliated Hospital of Dali University, Dali University; 4. Department of Biochemistry and Molecular Biology, College of Life Sciences, Yunnan University; 5. Department of Surgery, Health Science Center, College of Clinical Medicine, Dali UniversityShow moreShow less
Hepatic arterial infusion chemotherapy plus lenvatinib with or without PD-1 inhibition for unresectable hepatocellular carcinoma: a retrospective cohort study
Haidong Yu; Cunkai Ma; Cairang Yangdan; Haiming Yang; Xiaolei XuShow moreShow less
1. Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Qinghai University; 2. Department of Interventional Therapy, The Affiliated Hospital of Qinghai UniversityShow moreShow less
Longitudinal acquisition and infection risk associated with multidrug-resistant organisms and Candida colonization in intensive care unit patients
Ülkü Altoparlak; Hatice Erdoğan; Mine Çelik; Gülden AksuShow moreShow less
1. Department of Medical Microbiology, Haseki Training and Research Hospital; 2. Department of Anesthesiology and Reanimation, Haseki Training and Research HospitalShow moreShow less
FAQ
How long does JOURNAL OF CHEMOTHERAPY take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for JOURNAL OF CHEMOTHERAPY. The fastest paper went from submission to acceptance in 40 days (Combination therapy does not decrease 30-day mortality but increases antibiotic consumption in methicillin-sensitive S. aureus bacteraemia, received 2025-07-18, accepted 2025-08-27); the slowest took 260 days. The average is 108.9 days and the median is 91 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
